Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells.

RUNX1 is generally considered a tumor suppressor in myeloid neoplasms. Inactivating RUNX1 mutations have frequently been found in patients with myelodysplastic syndrome (MDS) and cytogenetically normal acute myeloid leukemia (AML). However, no somatic RUNX1 alteration was found in AMLs with leukemogenic fusion proteins, such as core-binding factor (CBF) leukemia and MLL fusion leukemia, raising the possibility that RUNX1 could actually promote the growth of these leukemia cells. Using normal human cord blood cells and those expressing leukemogenic fusion proteins, we discovered a dual role of RUNX1 in myeloid leukemogenesis. RUNX1 overexpression inhibited the growth of normal cord blood cells by inducing myeloid differentiation, whereas a certain level of RUNX1 activity was required for the growth of AML1-ETO and MLL-AF9 cells. Using a mouse genetic model, we also showed that the combined loss of Runx1/Cbfb inhibited leukemia development induced by MLL-AF9. RUNX2 could compensate for the loss of RUNX1. The survival effect of RUNX1 was mediated by BCL2 in MLL fusion leukemia. Our study unveiled an unexpected prosurvival role for RUNX1 in myeloid leukemogenesis. Inhibiting RUNX1 activity rather than enhancing it could be a promising therapeutic strategy for AMLs with leukemogenic fusion proteins.

[1]  S. Lowe,et al.  The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;NrasG12D acute myeloid leukemia , 2013, Oncogene.

[2]  Thomas A. Milne,et al.  RUNX1 Is a Key Target in t(4;11) Leukemias that Contributes to Gene Activation through an AF4-MLL Complex Interaction , 2013, Cell reports.

[3]  W. Reinhold,et al.  Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1–CBFβ interaction , 2012, Proceedings of the National Academy of Sciences.

[4]  S. Sugano,et al.  Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. , 2012, Blood.

[5]  G. Marcucci,et al.  The thrombopoietin/MPL/Bcl-xL pathway is essential for survival and self-renewal in human preleukemia induced by AML1-ETO. , 2012, Blood.

[6]  A. Kraft,et al.  Multiple phosphorylation sites are important for RUNX1 activity in early hematopoiesis and T‐cell differentiation , 2012, European journal of immunology.

[7]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[8]  S. Armstrong,et al.  Polycomb repressive complex 2 is required for MLL-AF9 leukemia , 2012, Proceedings of the National Academy of Sciences.

[9]  D. Tenen,et al.  The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations. , 2011, Blood.

[10]  David A. Williams,et al.  Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia. , 2011, Blood.

[11]  J. Maciejewski,et al.  p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia , 2011, Leukemia.

[12]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[13]  S. Robson,et al.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.

[14]  Sahar Mansour,et al.  Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome) , 2011, Nature Genetics.

[15]  S. Fröhling,et al.  AKT/FOXO Signaling Enforces Reversible Differentiation Blockade in Myeloid Leukemias , 2011, Cell.

[16]  M. Kurokawa,et al.  Loss of AML1/Runx1 accelerates the development of MLL-ENL leukemia through down-regulation of p19ARF. , 2011, Blood.

[17]  Anna L. Brown,et al.  Heritable GATA2 Mutations Associated with Familial Myelodysplastic Syndrome and Acute Myeloid Leukemia , 2011, Nature Genetics.

[18]  Lars Bullinger,et al.  MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. , 2011, Cancer cell.

[19]  T. Suda,et al.  Faculty Opinions recommendation of A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. , 2011 .

[20]  J. Mulloy,et al.  Molecular pathogenesis of core binding factor leukemia: current knowledge and future prospects , 2011, International journal of hematology.

[21]  T. Haferlach,et al.  RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. , 2011, Blood.

[22]  M. Carroll,et al.  AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3 , 2010, Leukemia.

[23]  Martin Dugas,et al.  Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  H. Drexler,et al.  Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders , 2010, Nature Genetics.

[25]  R. Kuiper,et al.  Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes , 2010, Nature Genetics.

[26]  Takeshi Corpora,et al.  Accelerated leukemogenesis by truncated CBF beta-SMMHC defective in high-affinity binding with RUNX1. , 2010, Cancer cell.

[27]  S. Anderson,et al.  Cbfb/Runx1 repression-independent blockage of differentiation and accumulation of Csf2rb-expressing cells by Cbfb-MYH11. , 2010, Blood.

[28]  K. Link,et al.  Core binding factor at the crossroads: Determining the fate of the HSC , 2010, Journal of cellular physiology.

[29]  D. Littman,et al.  Stem cell exhaustion due to Runx1 deficiency is prevented by Evi5 activation in leukemogenesis. , 2007, Blood.

[30]  Chieh-Yu Liu,et al.  AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. , 2009, Blood.

[31]  T. Haferlach,et al.  Characterization of a new myeloid leukemia cell line with normal cytogenetics (CG-SH). , 2009, Leukemia research.

[32]  R. Arceci.  PML targeting eradicates quiescent leukaemia-initiating cells , 2009 .

[33]  M. Wunderlich,et al.  Model systems for examining effects of leukemia-associated oncogenes in primary human CD34+ cells via retroviral transduction. , 2009, Methods in molecular biology.

[34]  M. Wunderlich,et al.  Transforming human blood stem and progenitor cells: A new way forward in leukemia modeling , 2008, Cell cycle.

[35]  Yi Zheng,et al.  Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. , 2008, Cancer cell.

[36]  P. Andreassen,et al.  p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death. , 2007, Blood.

[37]  D. Littman,et al.  Runx1 Protects Hematopoietic Stem/Progenitor Cells from Oncogenic Insult , 2007, Stem cells.

[38]  D. Littman,et al.  Repression of interleukin-4 in T helper type 1 cells by Runx/Cbfβ binding to the Il4 silencer , 2007, The Journal of experimental medicine.

[39]  M. Wunderlich,et al.  Human CD34 cells expressing the inv(16) fusion protein exhibit a myelomonocytic phenotype with greatly enhanced proliferative ability , 2006 .

[40]  M. Kurokawa.  AML1/Runx1 as a Versatile Regulator of Hematopoiesis: Regulation of Its Function and a Role in Adult Hematopoiesis , 2006, International journal of hematology.

[41]  Theresa A. Storm,et al.  Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways , 2006, Nature.

[42]  H. Hosoi,et al.  Shared and distinct roles mediated through C-terminal subdomains of acute myeloid leukemia/Runt-related transcription factor molecules in murine development. , 2005, Blood.

[43]  J. Kutok,et al.  Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. , 2004, Blood.

[44]  S. Ogawa,et al.  The transcriptionally active form of AML1 is required for hematopoietic rescue of the AML1-deficient embryonic para-aortic splanchnopleural (P-Sp) region. , 2004, Blood.

[45]  T. Kyo,et al.  High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. , 2004, Blood.

[46]  S. Ogawa,et al.  AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis , 2004, Nature Medicine.

[47]  S. Jhanwar,et al.  Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. , 2003, Blood.

[48]  C. Eaves,et al.  Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors , 2003, Leukemia.

[49]  K. MacKenzie,et al.  The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. , 2002, Blood.

[50]  John C Rockett,et al.  Arrays of DNA-binding sites , 2001, Genome Biology.

[51]  Cheng Li,et al.  Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application , 2001, Genome Biology.

[52]  Yoshiaki Ito,et al.  Dimerization with PEBP2β protects RUNX1/AML1 from ubiquitin–proteasome‐mediated degradation , 2001, The EMBO journal.

[53]  M. Kurokawa,et al.  Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. , 2000, Blood.

[54]  J. Zhang,et al.  The AML1/ETO fusion protein activates transcription of BCL-2. , 1996, Proceedings of the National Academy of Sciences of the United States of America.